hyperparathyroidism
HYPERPARATHYROIDISM

Hyperparathyroidism is a condition wherein there is an excessive production of parathyroid hormone (PTH).

Primary hyperparathyroidism is the most common endocrine disorder and an important cause of hypercalcemia in ambulatory patients.

Classic signs and symptoms include bone disease, kidney stones and hypercalcinosis.

Primary goal of pharmacological therapy is to normalize calcium levels.

 

Definition

  • Caused by excessive parathyroid hormone (PTH) production

Signs and Symptoms

  • Usually related to elevated levels of PTH & serum calcium
  • Classic signs & symptoms include bone disease, kidney stones & hypercalcinosis
  • Constipation
  • Hypertension
  • Muscle weakness
  • Nausea
  • Polydipsia
  • Polyuria
  • Psychiatric symptoms (depression, anxiety, etc)
  • Significant loss of appetite

Epdemiology

  • Primary hyperparathyroidism is the most common endocrine cause of hypercalcemia in ambulatory patients
  • Occurs more in women than in men aged >50 years old
  • 85-95% of primary hyperparathyroidism is due to adenoma
  • Sporadically arising solitary parathyroid adenoma is the most common primary hyperparathyroidism (PHPT)
  • Familial syndromes - 2nd most common cause of PHPT
  • Renal failure - most common cause of secondary hyperparathyroidism
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 09 Aug 2019
Uric acid-lowering therapy for gout also confers benefits for hyperlipidaemia, with febuxostat delivering greater reductions in cholesterol and triglyceride concentrations in the blood as compared with allopurinol and benzbromarone, according to a recent study.
Roshini Claire Anthony, 08 Apr 2019

About one-third of individuals who achieved remission of type 2 diabetes (T2D) after losing weight with an intensive weight management programme sustained their remission at 2 years, according to long-term results of the DiRECT* trial.

31 Jul 2019
New drug applications approved by US FDA as of 16 - 31 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
5 days ago
Chronic exposure to higher cortisol levels among patients with Turner syndrome (TS) is linked to short stature and greater total cholesterol levels, according to a study. Cortisol exposure also contributes to an increase in cardiovascular disease risk.